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Abstract: The aim of the current study is to identify the potential biomarkers involved in 
Hepatocellular carcinoma (HCC) carcinogenesis. A comparative proteomics approach was 
utilized to identify the differentially expressed proteins in the serum of 10 HCC patients 
and 10 controls. A total of 12 significantly altered proteins were identified by mass 
spectrometry. Of the 12 proteins identified, HSP90 was one of the most significantly 
altered proteins and its over-expression in the serum of 20 HCC patients was confirmed 
using ELISA analysis. The observations suggest that HSP90 might be a potential 
biomarker for early diagnosis, prognosis, and monitoring in the therapy of HCC. This work 
demonstrates that a comprehensive strategy of proteomic identification combined with 
further validation should be adopted in the field of cancer biomarker discovery.  
Keywords: proteomics; hepatocellular carcinoma; serum biomarker 
 
OPEN ACCESSInt. J. Mol. Sci. 2010, 11                 
 
 
1424
1. Introduction 
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, the fifth most common 
cancer and the third leading cause of cancer-related death in the world [1,2]. The incidence of HCC is 
rising around the world with few exceptions. There is a distinct geographical variation in the incidence 
of HCC, with 81% of cases occurring in the developing world and 54% of these occurring in China 
[3]. Current curative options can be applied to a paucity of patients, and in general, the prognosis of 
HCC is dismal due to underlying cirrhosis as well as to poor tumor response to chemotherapeutic 
regimes [4,5]. Currently, there is an urgent need to devise critical tools for the early diagnosis of and 
the monitoring of disease progression. Among these tools, validated biomarkers are viewed as the most 
important; therefore there is a critical need to discover new specific biomarkers in HCC.  
Proteomic analysis is currently considered to be a powerful tool for global evaluation of protein 
expression, and proteomics has been widely applied in analysis of diseases, especially in the field of 
cancer research [6–9]. Biomarker discovery and validation is a central application in current proteomic 
research to improve the diagnosis, treatment monitoring and prognosis of many kinds of cancer [6–9]. 
It has been thought that the association between protein alterations and malignancy―analysis of the 
cancer proteome―could be more informative and advantageous than genomics or transcriptomics 
alone, because there are also factors relating to molecular changes in translation, post-translational 
modification and intracellular mislocalization involved in tumor initiation and growth [10,11].   
Two-dimensional gel electrophoresis (2-DE) is an established technology for the separation of 
proteins. Despite a number of limitations, the resolution of 2-DE gels is impressive, rendering this 
technology still a preferred tool in many proteomics studies [12,13]. 2-DE gels can also give both 
qualitative and quantitative analysis and has been applied to proteomic studies in several human 
cancers, such as colorectal cancer, breast cancer, lung cancer, gastric cancer, prostate cancer, 
pancreatic cancer, etc. [14–19]. 
Plasma/serum peptides or proteins that are biological indicators are known as biomarkers. 
Serological biomarker detection promises noninvasive and financially reasonable screening for early 
cancer with a high potential of positive impact on survival and quality of life and therefore the 
potential to greatly enhance screening acceptance [9,20]. Alphafetoprotein (AFP), the only clinically 
available serum marker, has been widely used for serological diagnosis of human HCC. However, the 
measurement of AFP is not an ideal method for screening individuals at risk of developing HCC due to 
its poor sensitivity and specificity [21–24]. Therefore, the search is still ongoing to improve early and 
specific detection and disease monitoring. In the present study, 2-DE and MALDI-TOF MS were 
employed to investigate protein expression alterations between HCC and control serum samples. The 
aim of our study was to identify novel tumor-associated molecules for potential biomarkers using  
2-DE based differential proteomics. 
2. Materials and Methods 
2.1. Serum Sample Collection 
Blood samples were collected from 20 patients with HCC consulted for medical care without any 
previous treatment and 20 healthy donors under fasting conditions. Patients were admitted for HCC Int. J. Mol. Sci. 2010, 11                 
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surgery, and the HCC was confirmed by pathohistology after surgery. The age range of the healthy 
donors matched that of the patients. Blood drawn from both donors and patients was allowed to 
coagulate at room temperature for 10 min and then centrifuged at 3,000 g for 10 min. Serum were then 
stored at −80 °C. Written informed consent of all patients and blood donors was documented, and 
anonymity was maintained by tracing the patients through their clinical history number. The project 
was approved by the Scientific and Ethical Committee of the Chendu Medical Collegue, China. 
2.2. Serum High-Abundance Protein Depletion 
Serum samples from 10 HCC patients and 10 healthy controls were processed to deplete the top-6 
(albumin, IgG, IgA, antitrypsin, transferrin, and haptoglobin) high abundance proteins using the 
Agilent Multiple Affinity Removal System (Agilent Technologies, Palo Alto, CA) with previously 
published protocols [25,26]. Samples were processed according to the manufacturer’s instructions. For 
each sample, a low abundance fraction was collected, and buffer was exchanged into 10 mM Tris-HCl 
(pH 7.4) using 5,000 Da molecular weight cut-off spin concentrators (Agilent Technologies, Palo Alto, 
CA). Protein concentration was measured by bicinchoninic acid (BCA) protein assay.  
2.3. Two-dimensional Gel Electrophoresis  
All reagents and apparatus used have been described in detail elsewhere [27,28]. Two hundred 
microliters of serum was mixed with 400 μL of ice-cold acetone (−20 °C) and centrifuged at 10,000 g 
at 4 °C for 10 min. The pellet was mixed with 10 μL of a solution containing 10% sodium dodecyl 
(SDS) (w/v) and 2.3% dithioerythritol (DTE) (w/v). The sample was heated to 95 °C for 5 min, then 
diluted to 60 μL with a solution containing 8 M urea, 4% 3-[(3-cholamidopropyl)dimethylammonio]-
1-propanesulfonic acid (CHAPS) (w/v), 40 mM Tris, 65 mM DTE, and a trace of bromphenol blue. 
The whole final diluted CSF sample corresponding to 50 μg was loaded in a cup at the cathodic end of 
the immobilized pH gradient (IPG) strips. 2-DE was performed as described previously [29–32]. IEF 
was performed on rehydrated 18 cm Immobiline Drystrip gels, pH 3–10 NL following the manual of 
Amersham Biosciences. Vertical acrylamide-bisacrylamide gradient gels (9–16% T, 2.6% C) were 
used for 2D electrophoresis. 
2.4. Image Analysis 
Image analysis was performed using PDQuest 2D-analysis software (Bio-Rad, Hercules, CA). Spot 
intensity was quantified automatically by calculation of spot volume after normalization of the image 
by taking the ratio of intensity of one spot to the total spots, and expressed as a fractional intensity. 
Only those spots with 3.5-fold (t test, P < 0.05) or more changes in expression intensity were selected 
for MALDI-TOF-MS analysis.  
2.5. Tryptic Digestion 
Protein spots of interest were excised and destained with 25 mM ammonium bicarbonate, 50% 
ACN. Gels were then dried completely by centrifugal lyophilization. In-gel digestion was performed 
with 0.01 μg/μL trypsin in 25 mM ammonium bicarbonate for 15 h at 37 °C. Each spot was digested Int. J. Mol. Sci. 2010, 11                 
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overnight in 12.5 ng/mL trypsin in 0.1 M NH4HCO3. The peptides were extracted three times with 
50% ACN, 0.1% TFA. The extracts were pooled and dried completely by centrifugal lyophilization. 
2.6. Protein Identification by MALDI-TOF 
MALDI-TOF MS analysis of the samples was carried out on a mass spectrometer Autoflex (Bruker 
Daltonics) in a positive ion reflector mode. The ion acceleration voltage was 20 kV. Each spectrum 
was internally calibrated with the masses of two trypsin autolysis products. For PMF identification, the 
tryptic peptide mass maps were transferred with the MS BioToolsTM program (Bruker Daltonics) 
using MASCOT software (Matrix Science). Then the National Center for Biotechnology nonredundant 
(NCBInr) database was searched with human as the taxonomy. Up to one missed tryptic cleavage was 
considered and a mass accuracy of 100 ppm was used for all the tryptic-mass searches. 
2.7. ELISA for HSP90 
Human HSP90 ELISA kits (Adlitteram Diagnostic Laboratories) were used according to the 
manufacturer’s instructions to detect serum HSP90 levels. Briefly, 100 μL of a standard was dispensed 
into each of eight wells, and 100 μL of specimens, including 20 serum samples of HCC patients and  
20 serum samples of normal controls, were dispensed into plate wells. After dispensing 50 μL of 
enzyme conjugate reagent into each well, the solutions were gently mixed for 15 s. Then, the plate was 
incubated at 37 °C for 60 min. After removal of the mixture from the incubator, the microtiter wells 
were rinsed with deionized water and emptied five times. Then, the wells were sharply stricken onto 
absorbent paper to remove residual water droplets. Subsequently, 50 μL of color A and color B 
Reagent was added to each well, and the solutions were incubated at 37 °C for 15 min. The reaction 
was stopped with the addition of 50 μL of stop solution into each well and gently mixed for 30 s. It is 
important that all the blue color changes completely to yellow in each well and that the optical density 
is read at 450 nm within 30 min in a microtiter plate reader. 
3. Results 
3.1. Differential Protein Expression in HCC Patients Included in the Study 
The protein expression profiles in the serum of HCC and healthy controls were obtained by 2-DE. 
Gel images and representative 2-DE maps were unambiguously matched by the PD-Quest software, 
and displayed well-resolved and reproducible profiles for both HCC and normal healthy controls. 
Aprroximately 500–800 protein spots were detected by Coomassie brilliant blue staining in a single  
2-DE gel. The quantity of each spot in a gel was normalized as a percentage of the total quantity of all 
spots in the gel. In comparison with 2-DE patterns, differentially expressed proteins were defined as 
statistically meaningful on the basis of 3.5-fold up-regulation and 3.5-fold down-regulation in HCC 
patients compared with healthy controls or more changes in expression intensity (P < 0.05). According 
to these crtiteria, 35 spots were selected and analyzed using MALDI-TOF-MS. A total of 12 proteins 
from the 35 spots were identified (Table 1). One of the proteins, HSP90, was found to show the most 
significant differences in expression between HCC (129.0 ± 4.583) and normal healthy controls   
(18.33 ± 1.453) (P < 0.0001). HSP90 was up-regulated more than 7-fold in the serum of HCC when Int. J. Mol. Sci. 2010, 11                 
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compared with the normal healthy controls (Figure 1), and the representative map of mass 
spectrometry was shown in Figure 2. Redundancy of proteins that appeared in the database under 
different names and accession numbers was eliminated. If more than one protein was identified in one 
spot, the single protein member with the highest protein score (top rank) was singled out from the 
multiprotein family.  
Table 1. Differentially expressed proteins identified by MALDI-TOF PMF in the serum of 
hepatocellular carcinoma and normal healthy controls. 
Spot 
Number 
Protein name  MW 
(kDa)
pI Fold  change 
(Ca/N) 
P value 
(t test) 
1  S-adenosylmethionine synthetase isoform type-1  43.6  5.86 4.21  0.005 
2 Glycine  N-methyltransferase  32.6  6.58 4.56  0.007 
3 Haptoglobin  precursor  38.9  6.42 5.10  0.004 
4  Serum amyloid P-component precursor  25.4  6.10 3.84  0.018 
5 Glyceraldehyde-3-phosphate  dehydrogenase  35.9  8.58 5.73  0.003 
6  Heat shock protein 90  83.1  4.97 7.04  <0.0001 
7 Annexin  V  35.8  4.98 3.89  0.012 
8  Carbonic anhydrase I   28.9  6.59 -6.73  0.002 
9 Beta-galactoside-binding  lectin  15.1  5.34 -6.09 <0.0001 
10  Vitamin D-binding protein  52.8  5.20 -5.24  0.004 
11 Apolipoprotein  A-I  28.1  5.30 -3.59  0.017 
12 Annexin  4  36.1  5.80 -4.32  0.006 
 
Figure 1. Cropped 2-DE gel images of HSP90 in the serum of hepatocellular carcinoma 
patients and normal healthy controls. HSP90 was shown the most significant differences in 
expression between HCC (129.0 ± 4.583) and normal healthy controls (18.33 ± 1.453)  
(P < 0.0001). It was up-regulated more than 7-fold in the serum of HCC when compared 
with the normal healthy controls. Ca, carcinoma; N, normal healthy controls. 
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Figure 2. Results of HSP90 as the representative protein identified using   
MALDI-TOF-MS. 
 
3.2. Validation of the Significantly Differentially-Expressed Protein HSP90 by ELISA 
Using a commercially available ELISA kit for HSP90 protein, the serum levels of the HSP90 
protein was quantified in all 40 individual serum samples (the 20 HCC patients and 20 normal healthy 
controls) by enzyme-linked immunosorbent assay in order to validate its potential as a candidate 
biomarker. As shown in Figure 3, the t-test showed that HSP90 in serum levels of HCC patients  
(164.7 ± 6.566 ng/mL) was significantly elevated when compared with the healthy controls   
(22.7 ± 2.728 ng/mL) (P < 0.0001), which correlates with the 2-DE results.  
Figure 3. Levels of the potential biomarker HSP90 in the serum of 20 HCC patients and 
20 normal healthy controls groups as measured by ELISA assay. The t-test showed that 
HSP 90 in serum levels of HCC patients (164.7 ± 6.566 ng/mL) were significantly elevated 
when compared with the healthy controls (22.7 ± 2.728 ng/mL) (P < 0.0001). 
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4. Conclusions 
Biomarker searching and tumor profiling in HCC has been intensively carried out in recent years by 
using DNA microarray technology [33–36]. In general, there have been many discrepancies in the 
deregulated genes reported by those publications, indicating a high variability in the results depending 
on the type of platform used (oligos, cDNA, etc.) and the type of samples. At the moment, there are no 
clear candidates for biomarkers of tumor progression or early stages in HCC derived from genomic 
studies. Because the functional molecules in cells are proteins, proteome analysis is believed to have 
an advantage over cDNA microarray for clinical use. Proteomics provides the complementary 
information to that obtained from mRNA profiling by microarray [37,38]. Proteomic researches could 
lead to the molecular characterization of cellular events associated with cancer progression, cellular 
signaling, and developmental stages [39,40]. Proteomic researches of clinical cancer samples have led 
to the identification of cancer-specific protein biomarkers, which could provide a basis for developing 
new methods for early diagnosis and early detection [41].  
In the present study, we compared the global protein profiles between the serum of HCC patients 
and normal controls using a 2-DE and MALDI-TOF-MS approach. This approach makes no 
assumptions about known or unknown molecules, allowing the process to be independent of any 
presupposed hypotheses. A total of 12 differentially expressed proteins were identified, most of which 
were involved in the biological process, including cell transformation, protein folding, cell 
proliferation and apoptosis, and so on, which usually play important roles in the malignant initiation 
and development. Of the 12 identified proteins, seven proteins were up-regulated and five proteins 
were down-regulated in the serum of HCC. HSP90 shows one of the most significant changes between 
the serum of HCC and normal controls, and the mass spectrometric identification of HSP90 was also 
reliable. After showing significant elevation of HSP90 in the serum of HCC patients when compared 
with the serum of normal healthy controls, the result was validated by ELISA to test the levels of 
HSP90 in the serum of HCC patients and healthy controls. The results showed that the mean serum 
level of HSP90 in HCC patients was significant higher than in normal healthy controls, which 
correlated with the 2-DE results. 
Hsp90 is an essential chaperon for function and integrity of a wide range of oncogenic client 
proteins [42]. Hsp90 is 2-fold to 10-fold overexpressed in tumors, compared with normal tissues [43]. 
With respect to HCC, Hsp90 overexpression has been described and is associated with a poor 
prognosis [44]. Recently, several studies have found that the molecular chaperone Hsp90 constitutes a 
relevant therapeutic target in various types of cancer [45,46]. Oncogenic transcription factors and 
signaling intermediates have been identified as Hsp90 client proteins, including hypoxia-inducible-
factor-1(HIF-1), signal transducer and activator of transcription-3 (STAT3), intracellular kinases (Akt, 
Erk), and growth-factor receptors [47]. It has been demonstrated that HSP90 controls the folding and 
activity of numerous bona fide oncoproteins to which malignant cells become addicted, and hence it 
safeguards the dysregulated expression of these proteins and their mutational status [48]. Hsp90 up-
regulation in combination with cyclin-dependent kinase 4 (CDK4) activity, has been predicted to 
contribute to HCC development [44]. Therefore, HSP90 inhibition is anticipated to surpass targeted 
therapies that exclusively attack one oncoprotein, the function of which might be compensated via 
collateral pathways [45–47]. Int. J. Mol. Sci. 2010, 11                 
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The finding of the current study suggested that HSP90 expression has potential clinical impact. 
However, the sample size in the current study is relatively small, indicating that the proteomic data 
need to be confirmed in a study employing a great number of patients and healthy controls in the 
future. Moreover, more patient-centered and much larger sample numbers are required. Such an 
approach is in concordance with the conclusions of the Worldwide Strategic Consensus Conference on 
Biomarker Research; that biomarker research efficiently translates any finds into reduced mortality 
and morbidity from disease [49–51]. However, biomarkers are known to have the potential to 
dramatically alter options and strategies of diagnosis and treatment, and consequently a complex 
process with multiple steps of further analyses is necessary for translating our pilot proteomic 
observations into clinical applications in the future.  
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